Introduction: Rotavirus-From Basic Research To A Vaccine by Glass, Roger I. et al.
Sl
Introduction: Rotavirus-from Basic Research to a Vaccine
Roger I. Glass, Dennis R. Lang, Bernard N. Ivanoff,
and Richard W. Compans
In 1976, Jon Rohde, highlighting the importance of diarrhea
as a prime killer of children in the developing world, beckoned
the scientific community to "take science where the diarrhea
is!" [1]. While researchers were discovering many new etio-
logic agents that cause diarrhea, progress in preventing diar-
rheal deaths-then estimated at about 5 million per year-
was slow. Twenty years later, despite massive efforts to prevent
diarrheal mortality with programs of oral rehydration therapy,
diarrhea still ranks as the first or second most common cause
of death and disability-adjusted life years lost among children
in developing countries [2, 3]. An estimated 3-3.2 million
children still die each year from diarrhea (23 deaths/1000 live
births), making diarrheal disease a major contributor to infant
mortality in the developing world. The need for simple, effec-
tive7 ~nci inexpensive interventions, not only to treat diarrhea
but to prevent its occurrence, is urgent and abundantly clear.
The discovery of rotavirus by Bishop and colleagues in 1973
initiated a line of research that has progressed rapidly toward
the goal of prevention of rotavirus diarrhea by vaccination [4].
First was the development of simple, sensitive, and inexpensive
diagnostic tests that allowed epidemiologists to search for ro-
tavirus in fecal specimens of children with diarrhea [5]. Rotavi-
rus proved to be the most common cause of severe diarrhea,
responsible for 20%-70% of hospitalizations for diarrhea
among children worldwide [6,7]. Moreover, diarrhea was tradi-
tionally considered to be a disease spread by fecally contami-
nated food and water or by poor hygiene and, thus, concentrated
among children in the developing countries; however, rotavirus
is a "democratic" virus that infects nearly all children in the
world, rich or poor, by the age of 3-5 years. Clearly, improve-
ments in food, water, or hygiene would have little impact on
the control of rotavirus infection. Although early studies docu-
mented the tremendous disease burden of rotavirus, little could
be done to prevent disease.
The prospect that vaccines might prevent rotavirus in chil-
dren was appreciated early. Natural immunity was suggested
by the concentration of disease among children in the first 2
years of life and the decreased incidence of disease with in-
creasing age [8-11]. Follow-up of infants neonatally infected
with rotavirus confirmed that subsequent rotavirus infections
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were associated with less severe diarrhea. The discovery of
methods to propagate rotavirus provided a simple technique to
prepare vaccine seed lots by using traditional methods of tissue
culture and allowed work with the virus to proceed in the
laboratory .
The first rotavirus vaccine was tested by Vesikari et al. [12]
in 1983, and the success of these trials laid the groundwork
for the current strategy for vaccine development. A single oral
dose of a live vaccine prepared from a bovine rotavirus was
effective (> 80%) in preventing clinically significant rotavirus
diarrhea in Finnish infants. This led to a flurry of studies to
identify immune proxies for protection, animal models of dis-
ease, and ways to increase the efficacy ofvaccines among other
populations by using the technique of gene segment reassert-
ment. These studies, methods, and results are all well described
in this supplement. The outcome h3S been the successful field
testing of several candidate reassortant live rotavirus vaccines.
While reassortant rotavirus vaccines are being prepared for
licensure in the United States, many research questions remain.
None of these live oral vaccines, like natural immunity itself,
is fully protective against rotavirus diarrhea. Hence, the door
is open for the development of an improved vaccine that might
immunize by a principle different from that of natural infection
with a live strain of rotavirus. Many approaches, such as the
use ofbaculovirus-expressed virus-like particles or naked DNA
vaccines, are discussed in this volume. Even though much has
been learned about immunity to rotavirus, current measures of
immunity are not reliable in predicting protection by vaccines,
and better measures are urgently needed. Animal models have
provided many insights into the pathogenicity and immune
mechanisms of rotavirus disease, but their relevance to human
disease is uncertain. While much is known about the gene-
coding assignments and structure-function relations of the vi-
rus, key principles, such as genes encoding virulence, attenua-
tion, or host range, are still being explored [13].
Despite these shortcomings in our understanding of many
rotavirus vaccine research issues, progress with live oral "Jen-
nerian" reassortant vaccines may soon lead to the first licensed
vaccine. Two field trials of the rhesus reassortant vaccine have
been completed, and a trial with a bovine reassortant candidate
vaccine has demonstrated similar efficacy [14- 16]. The consid-
erations for licensure by the US Food and Drug Administration
are reviewed in this supplement, as are the many hurdles that
remain to take these vaccines from licensure to widespread use
in the United States with the goal of disease reduction.
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The major presentations of the Fifth International Rotavirus
Vaccine Workshop are being published with the hope that
pediatricians, public health practitioners, and scientists in the
United States and abroad will be stimulated to consider how
this first vaccine can be used to specifically prevent the disease
burden of rotavirus diarrhea. Initial efforts to license and intro-
duce these vaccines have been targeted at children in the United
States and other industrialized countries where the disease bur-
den is measured in terms of doctor visits, hospitalizations, par-
ent work time lost, and overall cost [17]. Additional, more
dramatic, benefits lie in the prevention of rotavirus deaths
among children in developing countries, where more than 2000
deaths occur each day [18]. The ultimate goal of a rotavirus
vaccine should be its incorporation into the schedule of routine
childhood immunizations promoted by the World Health Orga-
nization's Expanded Programme for Immunization. The wide-
spread use of a rotavirus vaccine could go a long way toward
achieving the goals of world leaders who declared at the World
Summit for Children (New York City, 1990) their desire to
effect a "halving of child deaths caused by diarrhea and a one-
quarter reduction in the incidence of diarrheal disease by the
year 2000" [2]. Our next target must be the prevention of
rotavirus diarrhea among children in the developing world.
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